Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
10.21
+0.04 (0.39%)
At close: Jan 22, 2025, 4:00 PM
10.37
+0.16 (1.57%)
After-hours: Jan 22, 2025, 4:32 PM EST
Immunome Employees
Immunome had 55 employees as of December 31, 2023. The number of employees increased by 18 or 48.65% compared to the previous year.
Employees
55
Change (1Y)
18
Growth (1Y)
48.65%
Revenue / Employee
$184,164
Profits / Employee
-$5,551,782
Market Cap
637.28M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 55 | 18 | 48.65% |
| Dec 31, 2022 | 37 | -2 | -5.13% |
| Dec 31, 2021 | 39 | 16 | 69.57% |
| Dec 31, 2020 | 23 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
IMNM News
- 9 days ago - Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 20 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference - Business Wire
- 2 months ago - Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 2 months ago - Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference - Business Wire
- 3 months ago - Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 - Business Wire
- 3 months ago - Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium - Business Wire
- 3 months ago - Immunome Appoints Roee Shahar as Executive Vice President, Commercial - Business Wire